0.6174

15.52% 0.0787

Adaptimmune Therapeutics Plc Adr (ADAP)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$0.5387

Offen:

$0.5438

24-Stunden-Volumen:

787.30K

Relative Volume:

0.40

Marktkapitalisierung:

$137.84M

Einnahmen:

$175.04M

Nettoeinkommen (Verlust:

$-44.52M

KGV:

-1.1566

EPS:

-0.5338

Netto-Cashflow:

$-56.05M

1W Leistung:

+9.62%

1M Leistung:

-13.95%

6M Leistung:

-40.73%

1J Leistung:

-16.58%

1-Tages-Spanne:

$0.5438

$0.6282

1-Wochen-Bereich:

$0.5316

$0.6282

52-Wochen-Spanne:

$0.5316

$2.05

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile

Firmenname

Adaptimmune Therapeutics Plc Adr

Sektor

Healthcare (1188)

Branche

Biotechnology (670)

Telefon

44 1235 430000

Adresse

60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE

Mitarbeiter

449

Twitter

@Adaptimmune

Nächster Verdiensttermin

2024-12-13

Neueste SEC-Einreichungen

ADAP's Discussions on Twitter

Vergleichen Sie ADAP mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ADAP Adaptimmune Therapeutics Plc Adr	0.6175	137.84M	175.04M	-44.52M	-56.05M	-0.18
VRTX Vertex Pharmaceuticals Inc	406.76	103.71B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	716.49	78.28B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	626.00	36.77B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	236.34	30.35B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	115.83	27.32B	3.30B	-501.07M	1.03B	-2.1146

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-07-30	Eingeleitet	H.C. Wainwright	Buy
2024-05-30	Eingeleitet	Scotiabank	Sector Outperform
2023-03-24	Eingeleitet	Bryan Garnier	Buy
2023-01-03	Hochstufung	Guggenheim	Neutral → Buy
2022-11-09	Hochstufung	Mizuho	Neutral → Buy
2021-05-28	Eingeleitet	Barclays	Underweight
2020-04-22	Eingeleitet	Mizuho	Neutral
2019-08-02	Herabstufung	Guggenheim	Buy → Neutral
2019-05-31	Eingeleitet	ROTH Capital	Buy
2019-05-30	Fortgesetzt	Citigroup	Buy
2019-05-07	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2017-03-17	Eingeleitet	Wells Fargo	Market Perform
2016-10-24	Herabstufung	BofA/Merrill	Neutral → Underperform
2016-09-30	Eingeleitet	Raymond James	Outperform
2016-02-25	Eingeleitet	Citigroup	Buy
2015-06-01	Eingeleitet	BofA/Merrill	Neutral
2015-06-01	Eingeleitet	Guggenheim	Buy
2015-06-01	Eingeleitet	Leerink Partners	Outperform

Alle ansehen

Adaptimmune Therapeutics Plc Adr Aktie (ADAP) Neueste Nachrichten

Dec 23, 2024

AST SpaceMobile Inc Still Hasn’t Convinced Analysts? - Stocks Register

Dec 23, 2024

These Numbers Show Just How Powerful Standard Lithium Ltd (AMEX: SLI) Stock ‎Is - Stocks Register

Dec 23, 2024

What Did We Note About Insider Trading At Lithium Americas Corp (NewCo) (NYSE: LAC)? - Stocks Register

Dec 23, 2024

Workhorse Group Inc (NASDAQ: WKHS) Could Pass $3.5 In One Year Stock Forecast - Stocks Register

Dec 23, 2024

Barnes & Noble Education Inc (NYSE: BNED) -10.53% Decline Turns Investors Away - Stocks Register

Dec 23, 2024

Applied Digital Corporation (NASDAQ: APLD) Could Pass $10 In One Year Stock Forecast - Stocks Register

Dec 23, 2024

Asana Inc (NYSE: ASAN) Up 15.57% This Year: What Is Going To Happen Next - Stocks Register

Dec 23, 2024

Dec 16, 2024

Adaptimmune's SWOT analysis: TCR-T pioneer faces challenges in stock outlook - Investing.com

Dec 16, 2024

Dec 04, 2024

Adaptimmune's SWOT analysis: TCR-T therapy pioneer faces challenges post-FDA nod - Investing.com

Dec 04, 2024

Dec 02, 2024

Royal Dutch Shell Plc ADR (SHEL-N) QuotePress Release - The Globe and Mail

Dec 02, 2024

Nov 27, 2024

Mizuho lowers Adaptimmune price target by 50%, citing pipeline shifts and cost cuts - Investing.com

Nov 27, 2024

Nov 18, 2024

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)’s Stock Reduces -12.58%, Making It A Good Investment - Stocks Register

Nov 18, 2024

Analysts Predict Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) To Loss -577.97% From Current Levels. - Stocks Register

Nov 18, 2024

Nov 14, 2024

Earnings call: Adaptimmune outlines new strategy amid Tecelra launch By Investing.com - Investing.com South Africa

Nov 14, 2024

Adaptimmune stock holds Buy rating with lower target amid Q3 revenue outperformance - Investing.com

Nov 14, 2024

Nov 05, 2024

ADAPAdaptimmune Therapeutics plc American Depositary Shares Latest Stock News & Market Updates - StockTitan

Nov 05, 2024

Nov 01, 2024

Ready to Jump After Recent Trade: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News

Oct 16, 2024

Oct 14, 2024

Ratio Examination: Adaptimmune Therapeutics Plc ADR (ADAP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 14, 2024

Was anything negative for Adaptimmune Therapeutics Plc ADR (ADAP) stock last session? - US Post News

Oct 14, 2024

Oct 10, 2024

Chief Commercial Officer Piccina Cintia sale 24,531 shares of Adaptimmune Therapeutics Plc ADR [ADAP] - Knox Daily

Oct 10, 2024

Oct 09, 2024

The Significance of Moving Averages in Adaptimmune Therapeutics Plc ADR Inc. (ADAP) Price Performance - The InvestChronicle

Oct 09, 2024

Oct 08, 2024

Technical analysis of Adaptimmune Therapeutics Plc ADR (ADAP) stock chart patterns - US Post News

Oct 08, 2024

Oct 07, 2024